2025-11-15 - Analysis Report
Okay, here's an analysis of Schrodinger Inc. (SDGR) based on the data you provided.

**Report on Schrodinger Inc. (SDGR)**

Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1. Performance vs. S&P 500 (VOO)**

*   **Accumulated Return:**
    *   SDGR: -56.83%
    *   VOO: 66.77%
*   **Divergence:**
    *   Current: -118.4%
    *   Max: 42.2%
    *   Min: -121.2%
    *   Relative Divergence: 1.7%

**Analysis:** SDGR has significantly underperformed the S&P 500. The current divergence is near its historical minimum, suggesting a large performance gap. The Relative Divergence of 1.7 indicates the stock is at the very low end of its historical divergence range compared to the VOO, hinting that underperformance is at a maximum, so high risk is apparent

* **Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha    | Beta  | Cap(B) |
|------------|---------|-------|----------|-------|--------|
| 2020-2022  | -70.0%  | 78.2% | -76.0%   | 0.1   | 1.3    |
| 2021-2023  | -57.0%  | 81.0% | -59.0%   | -0.0   | 2.6    |
| 2022-2024  | 6.0%    | 81.0% | -14.0%   | -0.0   | 1.4    |
| 2023-2025  | -5.0%   | 82.6% | -68.0%   | -0.0   | 1.3    |

**Analysis:** The provided data indicates some significant volatility and underperformance. CAGR is negative in most periods, and the MDD is very high. The consistently negative Alpha suggests SDGR is underperforming relative to its risk-adjusted benchmark.  Beta fluctuates, indicating varying degrees of correlation with the market; in particular, we can see high volatility is maintained.

**2. Recent Price Action**

*   **Current Price:** 17.64
*   **Previous Close:** 17.2
*   **Change:** 2.56%
*   **5-day MA:** 17.882
*   **20-day MA:** 20.0535
*   **60-day MA:** 19.754

**Analysis:** The price has increased significantly from the previous close, suggesting a short-term positive movement, but it's still below the 5, 20, and 60-day moving averages, indicating potential resistance ahead.
The recent 2.56% price increase from the previous close is a positive sign, potentially signaling a short-term recovery.

**3. Technical Indicators & Return Expectations**

*   **MRI:** 0.8 (Medium Investment)
*   **RSI:** 20.24 (Oversold)
*   **PPO:** -1.92
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (47 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** 1.1 (Short-term increase)
*   **Expected Return:** -3643.7%

**Analysis:**  The RSI indicates the stock is oversold, potentially suggesting a buying opportunity. The PPO is negative, aligning with the stock's recent downtrend. The Hybrid Signal recommends investing the entire amount, implying that the system detects high safety, so the MRI is high(0.90). The recent increase in relative divergence and significant price movement from the previous close suggests short-term upward momentum. Despite the expected return is negative so, be careful for invest

**4. Recent News & Significant Events**

*   **Positive Highlights:** Articles from Zacks highlight SDGR as a "Buy the Bottom" stock. Insider Monkey mentions progress in the Neptune project.
*   **Mixed/Neutral:** Simply Wall St. questions the timing for Schrodinger after a price drop.
*   **Conference & Earnings:** Announcements of a presentation at the Jefferies London Healthcare Conference and Q3 earnings reports.

**Analysis:** Recent news presents a mixed picture. While some articles suggest a potential buying opportunity, others are more cautious. The Q3 earnings call is a significant event that investors will likely be watching closely.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy (~Buy)
*   **Opinions:** 9
*   **Target Price:** 27.33 (avg) / 33.00 (high) / 19.00 (low)
*   **Rating Changes:** (No details provided on specific changes)

**Analysis:** Analysts have a generally positive outlook on SDGR, with a consensus rating of "Strong Buy" and a target price well above the current price. However, it's important to consider the range of target prices, as the low end is closer to the current price.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue |
|------------|-------|---------|
| 2025-11-05 | -0.45 | 0.05 B$ |
| 2025-08-06 | -0.59 | 0.05 B$ |
| 2025-05-07 | -0.82 | 0.06 B$ |
| 2024-11-12 | -0.52 | 0.04 B$ |
| 2025-11-05 | -0.52 | 0.04 B$ |

**Analysis:** The company is consistently reporting losses (negative EPS). Revenue fluctuates but shows some stability in the recent quarters.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.05B  | 51.61%        |
| 2025-06-30   | $0.05B  | 47.77%        |
| 2025-03-31   | $0.06B  | 52.26%        |
| 2024-12-31   | $0.09B  | 72.61%        |
| 2024-09-30   | $0.04B  | 50.24%        |

**Capital and Profitability**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-09-30   | $0.32B  | -10.21%  |
| 2025-06-30   | $0.34B  | -12.59%  |
| 2025-03-31   | $0.37B  | -16.01%  |
| 2024-12-31   | $0.42B  | -9.54%   |
| 2024-09-30   | $0.45B  | -8.49%   |

**Analysis:** Revenue has been relatively stable in recent quarters, with a significant spike in 2024-12-31. Profit margins are generally high. Equity has been decreasing, and the Return on Equity (ROE) is negative, reflecting losses and less efficient use of equity.

**7. Overall Analysis & Summary**

Schrodinger Inc. (SDGR) presents a mixed picture for potential investors.

*   **Negatives:** Significant underperformance compared to the S&P 500, negative earnings, decreasing equity, and negative ROE raise concerns about financial health and market sentiment. Also, the extremely negative expected return and high volatility must be noticed.
*   **Positives:** Analyst consensus is "Strong Buy" with a target price considerably higher than the current price. The stock is currently oversold, potentially offering a short-term buying opportunity. Recent news includes some positive highlights, such as "Buy the Bottom" recommendations.

**Recommendation:** Given the significant risks, investors should exercise caution. Further research is recommended, focusing on the company's growth strategy, profitability outlook, and the catalysts that analysts believe will drive future growth. The recent price surge warrants further investigation to determine if it marks the beginning of a sustained recovery or a short-term fluctuation.

